{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:37:11Z","timestamp":1789835831180,"version":"4.0.1"},"reference-count":219,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009281","name":"Fondation Thierry Latran","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>In the last four decades, monoclonal antibodies and their derivatives have emerged as a powerful class of therapeutics, largely due to their exquisite targeting specificity. Several clinical areas, most notably oncology and autoimmune disorders, have seen the successful introduction of monoclonal-based therapeutics. However, their adoption for treatment of Central Nervous System diseases has been comparatively slow, largely due to issues of efficient delivery resulting from limited permeability of the Blood Brain Barrier. Nevertheless, CNS diseases are becoming increasingly prevalent as societies age, accounting for ~6.5 million fatalities worldwide per year. Therefore, harnessing the full therapeutic potential of monoclonal antibodies (and their derivatives) in this clinical area has become a priority. Adeno-associated virus-based vectors (AAVs) are a potential solution to this problem. Preclinical studies have shown that AAV vector-mediated antibody delivery provides protection against a broad range of peripheral diseases, such as the human immunodeficiency virus (HIV), influenza and malaria. The parallel identification and optimization of AAV vector platforms which cross the Blood Brain Barrier with high efficiency, widely transducing the Central Nervous System and allowing high levels of local transgene production, has now opened a number of interesting scenarios for the development of AAV vector-mediated antibody delivery strategies to target Central Nervous System proteinopathies.<\/jats:p>","DOI":"10.3389\/fneur.2022.870799","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T08:21:26Z","timestamp":1649751686000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System"],"prefix":"10.3389","volume":"13","author":[{"given":"Marika","family":"Marino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"Nature."},{"key":"B2","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2165\/00003495-198937060-00004","article-title":"Muromonab CD3","volume":"37","author":"Todd","year":"1989","journal-title":"Drugs."},{"key":"B3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/00000441-200207000-00004","article-title":"Therapeutic applications of monoclonal antibodies","volume":"324","author":"Berger","year":"2002","journal-title":"Am J Med Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.tibtech.2018.05.014","article-title":"The increasingly human and profitable monoclonal antibody market","volume":"37","author":"Grilo","year":"2019","journal-title":"Trends Biotechnol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/312643a0","article-title":"Production of functional chimaeric mouse\/human antibody","volume":"312","author":"Boulianne","year":"1984","journal-title":"Nature."},{"key":"B6","doi-asserted-by":"publisher","first-page":"6851","DOI":"10.1073\/pnas.81.21.6851","article-title":"Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains","volume":"81","author":"Morrison","year":"1984","journal-title":"Proc Natl Acad Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/321522a0","article-title":"Replacing the complementarity-determining regions in a human antibody with those from a mouse","volume":"321","author":"Jones","year":"1986","journal-title":"Nature."},{"key":"B8","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/348552a0","article-title":"Phage antibodies: filamentous phage displaying antibody variable domains","volume":"348","author":"McCafferty","year":"1990","journal-title":"Nature."},{"key":"B9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/19420862.2018.1556465","article-title":"Antibodies to watch in 2019","volume":"11","author":"Kaplon","year":"2019","journal-title":"mAbs."},{"key":"B10","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/d41573-021-00079-7","article-title":"FDA approves 100th monoclonal antibody product","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov."},{"key":"B11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41531-018-0062-4","article-title":"Proteasome-targeted nanobodies alleviate pathology and functional decline in an \u03b1-synuclein-based Parkinson's disease model","volume":"4","author":"Chatterjee","year":"2018","journal-title":"npj Parkinson's Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"948","DOI":"10.3390\/genes12060948","article-title":"Administration of AAV-alpha synuclein NAC antibody improves locomotor behavior in rats overexpressing alpha synuclein","volume":"12","author":"Chen","year":"2021","journal-title":"Genes."},{"key":"B13","doi-asserted-by":"publisher","first-page":"12425","DOI":"10.1523\/JNEUROSCI.2016-16.2016","article-title":"Vectored intracerebral immunization with the anti-Tau monoclonal antibody PHF1 markedly reduces Tau pathology in mutant Tau transgenic mice","volume":"36","author":"Liu","year":"2016","journal-title":"J Neurosci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1038\/mt.2010.111","article-title":"A\u03b2-directed single-chain antibody delivery via a serotype-1 AAV vector improves learning behavior and pathology in Alzheimer's disease mice","volume":"18","author":"Ryan","year":"2010","journal-title":"Mol Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"11923","DOI":"10.1523\/JNEUROSCI.2795-06.2006","article-title":"Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice","volume":"26","author":"Levites","year":"2006","journal-title":"J Neurosci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.nbd.2006.04.012","article-title":"Anti-A\u03b2 single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease","volume":"23","author":"Fukuchi","year":"2006","journal-title":"Neurobiol Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1038\/mt.2009.174","article-title":"Generating differentially targeted amyloid-beta specific intrabodies as a passive vaccination strategy for Alzheimer's disease","volume":"17","author":"Sudol","year":"2009","journal-title":"Mol Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3233\/JAD-2011-110230","article-title":"Anti-amyloid-\u03b2 single-chain antibody brain delivery via AAV reduces amyloid load but may increase cerebral hemorrhages in an Alzheimer's disease mouse model","volume":"27","author":"Kou","year":"2011","journal-title":"JAD."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e57606","DOI":"10.1371\/journal.pone.0057606","article-title":"Prophylaxis and treatment of Alzheimer's disease by delivery of an adeno-associated virus encoding a monoclonal antibody targeting the amyloid beta protein","volume":"8","author":"Shimada","year":"2013","journal-title":"PLoS ONE."},{"key":"B20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s12031-012-9877-3","article-title":"Muscle-directed anti-A\u03b2 single-chain antibody delivery via AAV1 reduces cerebral A\u03b2 load in an Alzheimer's disease mouse model","volume":"49","author":"Yang","year":"2013","journal-title":"J Mol Neurosci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e0226245","DOI":"10.1371\/journal.pone.0226245","article-title":"Gene delivery of a modified antibody to A\u03b2 reduces progression of murine Alzheimer's disease","volume":"14","author":"Elmer","year":"2019","journal-title":"PLoS ONE."},{"key":"B22","doi-asserted-by":"publisher","first-page":"9340","DOI":"10.1523\/JNEUROSCI.22-21-09340.2002","article-title":"Abundant Tau filaments and non-apoptotic neurodegeneration in transgenic mice expressing human P301S Tau protein","volume":"22","author":"Allen","year":"2002","journal-title":"J Neurosci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1084\/jem.20162125","article-title":"AAV-mediated expression of anti-Tau scFvs decreases Tau accumulation in a mouse model of Tauopathy","volume":"214","author":"Ising","year":"2017","journal-title":"J Exp Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40478-018-0585-2","article-title":"Anti-Tau conformational scFv MC1 antibody efficiently reduces pathological Tau species in adult JNPL3 mice","volume":"6","author":"Vitale","year":"2018","journal-title":"Acta Neuropathol Commun."},{"key":"B25","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.ymthe.2020.10.007","article-title":"Anti-Tau scFvs targeted to the cytoplasm or secretory pathway variably modify pathology and neurodegenerative phenotypes","volume":"29","author":"Goodwin","year":"2021","journal-title":"Mol Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1172\/JCI123931","article-title":"Virus-mediated delivery of antibody targeting TAR DNA-binding protein-43 mitigates associated neuropathology","volume":"129","author":"Pozzi","year":"2019","journal-title":"J Clin Invest."},{"key":"B27","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/mt.2013.239","article-title":"Adeno-associated virus-mediated delivery of a recombinant single-chain antibody against misfolded superoxide dismutase for treatment of amyotrophic lateral sclerosis","volume":"22","author":"Patel","year":"2014","journal-title":"Mol Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.nbd.2018.08.021","article-title":"Single chain variable fragment antibodies directed against SOD1 ameliorate disease in mutant SOD1 transgenic mice","volume":"121","author":"Ghadge","year":"2019","journal-title":"Neurobiol Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/sj.mt.6300387","article-title":"CNS delivery of vectored prion-specific single-chain antibodies delays disease onset","volume":"16","author":"Wuertzer","year":"2008","journal-title":"Mol Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1097\/NEN.0b013e3181f530ec","article-title":"Early or late-stage anti-n-terminal huntingtin intrabody gene therapy reduces pathological features in b6.hdr6\/1 mice","volume":"69","author":"Snyder-Keller","year":"2010","journal-title":"J Neuropathol Exp Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/7120753","article-title":"An intrabody drug (rAAV6-INT41) reduces the binding of n-terminal huntingtin fragment(s) to dna to basal levels in pc12 cells and delays cognitive loss in the r6\/2 animal model","volume":"2016","author":"Amaro","year":"2016","journal-title":"J Neurodegen Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.euroneuro.2013.03.007","article-title":"Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders?","volume":"25","author":"Bayer","year":"2015","journal-title":"Eur Neuropsychopharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nrn2786","article-title":"Prion-like mechanisms in neurodegenerative diseases","volume":"11","author":"Frost","year":"2010","journal-title":"Nat Rev Neurosci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.neuron.2009.12.016","article-title":"The transcellular spread of cytosolic amyloids, prions, and prionoids","volume":"64","author":"Aguzzi","year":"2009","journal-title":"Neuron."},{"key":"B35","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1084\/jem.20120741","article-title":"Prion-like spread of protein aggregates in neurodegeneration","volume":"209","author":"Polymenidou","year":"2012","journal-title":"J Exp Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/ana.22615","article-title":"Pathogenic protein seeding in alzheimer disease and other neurodegenerative disorders","volume":"70","author":"Jucker","year":"2011","journal-title":"Ann Neurol."},{"key":"B37","first-page":"227","article-title":"Commentary: intracellular antibodies (intrabodies) versus RNA interference for therapeutic applications","volume":"35","author":"Cao","year":"2005","journal-title":"Ann Clin Lab Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/nan.12402","article-title":"Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease","volume":"43","author":"Covell","year":"2017","journal-title":"Neuropathol Appl Neurobiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nature14547","volume":"522","author":"Peelaerts","year":"2015","journal-title":"Nature."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1042\/BCJ20180297","article-title":"Impact of monomeric, oligomeric and fibrillar alpha-synuclein on astrocyte reactivity and toxicity to neurons","volume":"475","author":"Chavarr\u00eda","year":"2018","journal-title":"Biochem J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"32131","DOI":"10.1074\/jbc.M114.594846","article-title":"Monoclonal antibodies against A\u03b242 fibrils distinguish multiple aggregation state polymorphisms in vitro and in Alzheimer disease brain","volume":"289","author":"Hatami","year":"2014","journal-title":"J Biol Chem."},{"key":"B42","first-page":"347","article-title":"Antisense oligonucleotides: basic concepts and mechanisms","volume":"1","author":"Dias","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"B43","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1089\/ard.1991.1.141","article-title":"Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3\u2032 exonuclease in plasma","volume":"1","author":"Eder","year":"1991","journal-title":"Antisense Res Dev."},{"key":"B44","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S0140-6736(01)05629-X","article-title":"Antisense therapy in oncology: new hope for an old idea?","volume":"358","author":"Tamm","year":"2001","journal-title":"Lancet."},{"key":"B45","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nbt831","article-title":"Expression profiling reveals off-target gene regulation by RNAi","volume":"21","author":"Jackson","year":"2003","journal-title":"Nat Biotechnol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1261\/rna.25706","article-title":"Widespread siRNA \u201coff-target\u201d transcript silencing mediated by seed region sequence complementarity","volume":"12","author":"Jackson","year":"2006","journal-title":"RNA."},{"key":"B47","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1261\/rna5160904","article-title":"Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs)","volume":"10","author":"Persengiev","year":"2004","journal-title":"RNA."},{"key":"B48","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3389\/fimmu.2017.00771","article-title":"Nanobody technology: a versatile toolkit for microscopic imaging, protein-protein interaction analysis, and protein function exploration","volume":"8","author":"Beghein","year":"2017","journal-title":"Front Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/cts.12567","article-title":"Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development","volume":"11","author":"Ovacik","year":"2018","journal-title":"Clin Transl Sci."},{"key":"B50","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature."},{"key":"B51","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12967-020-02681-6","article-title":"Anti-migraine agents from an immunological point of view","volume":"19","author":"Assas","year":"2021","journal-title":"J Transl Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"a020412","DOI":"10.1101\/cshperspect.a020412","article-title":"The blood-brain barrier","volume":"7","author":"Daneman","year":"2015","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug Transport across the blood\u2013brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J Cereb Blood Flow Metab."},{"key":"B54","doi-asserted-by":"publisher","first-page":"84ra43","DOI":"10.1126\/scitranslmed.3002254","article-title":"A therapeutic antibody targeting BACE1 inhibits Amyloid-\u03b2 production in vivo","volume":"3","author":"Atwal","year":"2011","journal-title":"Sci Transl Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"688090","DOI":"10.3389\/fnins.2021.688090","article-title":"Blood\u2013brain barrier breakdown: an emerging biomarker of cognitive impairment in normal aging and dementia","volume":"15","author":"Hussain","year":"2021","journal-title":"Front Neurosci."},{"key":"B56","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood\u2013brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat Rev Neurol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12979-015-0029-9","article-title":"Blood-brain barrier dysfunction developed during normal aging is associated with inflammation and loss of tight junctions but not with leukocyte recruitment","volume":"12","author":"Elahy","year":"2015","journal-title":"Immun Ageing."},{"key":"B58","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.neuron.2015.09.036","article-title":"Lack of widespread BBB disruption in Alzheimer's disease models: focus on therapeutic antibodies","volume":"88","author":"Bien-Ly","year":"2015","journal-title":"Neuron."},{"key":"B59","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrn1824","article-title":"Astrocyte\u2013endothelial interactions at the blood\u2013brain barrier","volume":"7","author":"Abbott","year":"2006","journal-title":"Nat Rev Neurosci."},{"key":"B60","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.tibtech.2015.10.005","article-title":"Antibody approaches to treat brain diseases","volume":"34","author":"Neves","year":"2016","journal-title":"Trends Biotechnol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2045-8118-8-7","article-title":"Drug transport in brain via the cerebrospinal fluid","volume":"8","author":"Pardridge","year":"2011","journal-title":"Fluids Barriers CNS."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e0122453","DOI":"10.1371\/journal.pone.0122453","article-title":"Pharmacokinetics and bioavailability of a therapeutic enzyme (idursulfase) in cynomolgus monkeys after intrathecal and intravenous administration","volume":"10","author":"Xie","year":"2015","journal-title":"PLoS ONE."},{"key":"B63","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s13346-012-0073-3","article-title":"Delivery of proteins to CNS as seen and measured by positron emission tomography","volume":"2","author":"Papisov","year":"2012","journal-title":"Drug Deliv Transl Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pediatrneurol.2016.10.022","article-title":"Intracerebroventricular delivery as a safe, long-term route of drug administration","volume":"67","author":"Cohen-Pfeffer","year":"2017","journal-title":"Pediatr Neurol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/jmri.1880080126","article-title":"Brain edema development after MRI-guided focused ultrasound treatment","volume":"8","author":"M\u00f6rocz","year":"1998","journal-title":"J Magn Reson Imaging."},{"key":"B66","doi-asserted-by":"publisher","first-page":"604197","DOI":"10.3389\/fnins.2021.604197","article-title":"Large-volume intrathecal administrations: impact on CSF pressure and safety implications","volume":"15","author":"Belov","year":"2021","journal-title":"Front Neurosci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0006-8993(84)90254-3","article-title":"Hyperosmotic arabinose solutions open the tight junctions between brain capillary endothelial cells in tissue culture","volume":"302","author":"Dorovini-Zis","year":"1984","journal-title":"Brain Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.2174\/138920112800624364","article-title":"Ultrasound-induced blood-brain barrier opening","volume":"13","author":"Konofagou","year":"2012","journal-title":"Curr Pharm Biotechnol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1007\/s11095-009-9939-6","article-title":"Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery","volume":"26","author":"Pardridge","year":"2009","journal-title":"Pharm Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.celrep.2017.12.019","article-title":"Brain shuttle antibody for Alzheimer's disease with attenuated peripheral effector function due to an inverted binding mode","volume":"22","author":"Weber","year":"2018","journal-title":"Cell Rep."},{"key":"B71","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3390\/ph14060535","article-title":"Mathematical models of blood-brain barrier transport of monoclonal antibodies targeting the transferrin receptor and the insulin receptor","volume":"14","author":"Pardridge","year":"2021","journal-title":"Pharmaceuticals."},{"key":"B72","doi-asserted-by":"publisher","first-page":"5207","DOI":"10.1021\/acs.molpharmaceut.8b00730","article-title":"Blood-brain barrier transport, plasma pharmacokinetics, and neuropathology following chronic treatment of the rhesus monkey with a brain penetrating humanized monoclonal antibody against the human transferrin receptor","volume":"15","author":"Pardridge","year":"2018","journal-title":"Mol Pharm."},{"key":"B73","doi-asserted-by":"publisher","first-page":"183ra57","DOI":"10.1126\/scitranslmed.3005338","article-title":"Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier","volume":"5","author":"Couch","year":"2013","journal-title":"Sci Transl Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"84ra44","DOI":"10.1126\/scitranslmed.3002230","article-title":"Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target","volume":"3","author":"Yu","year":"2011","journal-title":"Sci Transl Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3109\/1061186X.2012.712132","article-title":"Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies","volume":"20","author":"Zhou","year":"2012","journal-title":"J Drug Target."},{"key":"B76","doi-asserted-by":"publisher","first-page":"261ra154","DOI":"10.1126\/scitranslmed.3009835","article-title":"Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates","volume":"6","author":"Yu","year":"2014","journal-title":"Sci Transl Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"Biodrugs."},{"key":"B78","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","article-title":"Adeno-associated virus serotypes: vector toolkit for human gene therapy","volume":"14","author":"Wu","year":"2006","journal-title":"Mol Ther."},{"key":"B79","doi-asserted-by":"publisher","first-page":"58960","DOI":"10.3791\/58960","article-title":"Production, purification, and quality control for adeno-associated virus-based vectors","volume":"143","author":"Fripont","year":"2019","journal-title":"J Vis Exp."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/hgtb.2015.140","article-title":"Expressing transgenes that exceed the packaging capacity of adeno-associated virus capsids","volume":"27","author":"Chamberlain","year":"2016","journal-title":"Hum Gene Ther Methods."},{"key":"B81","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.3390\/ijms20184388","article-title":"Gene therapy for ALS\u2014a perspective","volume":"20","author":"Cappella","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B82","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J Hepatol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41434-021-00243-z","article-title":"Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions","volume":"28","author":"Riyad","year":"2021","journal-title":"Gene Ther."},{"key":"B84","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40794-017-0046-0","article-title":"Vectored immunoprophylaxis: an emerging adjunct to traditional vaccination","volume":"3","author":"Sanders","year":"2017","journal-title":"Trop Dis Travel Med Vaccines."},{"key":"B85","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.coi.2015.06.014","article-title":"Engineering humoral immunity as prophylaxis or therapy","volume":"35","author":"Deal","year":"2015","journal-title":"Curr Opin Immunol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nbt.2618","article-title":"Broad protection against influenza infection by vectored immunoprophylaxis in mice","volume":"31","author":"Balazs","year":"2013","journal-title":"Nat Biotechnol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"254ra129","DOI":"10.1126\/scitranslmed.3009512","article-title":"Broadly neutralizing antibodies abrogate established hepatitis C virus infection","volume":"6","author":"de Jong","year":"2014","journal-title":"Sci Transl Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"12528","DOI":"10.1073\/pnas.1407362111","article-title":"Vectored antibody gene delivery protects against Plasmodium falciparum sporozoite challenge in mice","volume":"111","author":"Deal","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B89","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nature10660","article-title":"Antibody-based protection against HIV infection by vectored immunoprophylaxis","volume":"481","author":"Balazs","year":"2012","journal-title":"Nature."},{"key":"B90","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/nm.3471","article-title":"Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission","volume":"20","author":"Balazs","year":"2014","journal-title":"Nat Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"e230","DOI":"10.1016\/S2352-3018(19)30003-7","article-title":"Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial","volume":"6","author":"Priddy","year":"2019","journal-title":"Lancet HIV."},{"key":"B92","doi-asserted-by":"publisher","first-page":"734304","DOI":"10.3389\/fimmu.2021.734304","article-title":"Contribution to HIV prevention and treatment by antibody-mediated effector function and advances in broadly neutralizing antibody delivery by vectored immunoprophylaxis","volume":"12","author":"Phelps","year":"2021","journal-title":"Front Immunol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV serotypes 1\u20139 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol Ther."},{"key":"B94","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1089\/humc.2017.010","article-title":"Persistent expression of dopamine-synthesizing enzymes 15 years after gene transfer in a primate model of Parkinson's disease","volume":"28","author":"Sehara","year":"2017","journal-title":"Hum Gene Ther Clin Dev."},{"key":"B95","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1089\/hum.2020.269","article-title":"Safety of direct intraparenchymal AAVrh.10-mediated central nervous system gene therapy for metachromatic leukodystrophy","volume":"32","author":"Rosenberg","year":"2021","journal-title":"Hum Gene Ther."},{"key":"B96","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/gt.2011.130","article-title":"Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs","volume":"19","author":"Federici","year":"2012","journal-title":"Gene Ther."},{"key":"B97","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.omtm.2020.04.001","article-title":"Intra-CSF AAV9 and AAVrh10 administration in nonhuman primates: promising routes and vectors for which neurological diseases?","volume":"17","author":"Bey","year":"2020","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B98","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1089\/hum.2020.301","article-title":"Intracerebroventricular administration of AAV9-PHP.B SYN1-EmGFP induces widespread transgene expression in the mouse and monkey central nervous system","volume":"32","author":"Galvan","year":"2021","journal-title":"Hum Gene Ther."},{"key":"B99","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum Gene Ther."},{"key":"B100","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/brainsci10020119","article-title":"Management of neuroinflammatory responses to AAV-mediated gene therapies for neurodegenerative diseases","volume":"10","author":"Perez","year":"2020","journal-title":"Brain Sci."},{"key":"B101","doi-asserted-by":"publisher","first-page":"11556","DOI":"10.1128\/JVI.01536-06","article-title":"Structurally mapping the diverse phenotype of adeno-associated virus serotype 4","volume":"80","author":"Govindasamy","year":"2006","journal-title":"J Virol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"6947","DOI":"10.1128\/JVI.07232-11","article-title":"Structural insight into the unique properties of adeno-associated virus serotype 9","volume":"86","author":"DiMattia","year":"2012","journal-title":"J Virol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum Gene Ther."},{"key":"B104","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.omtm.2018.01.004","article-title":"Target-cell-directed bioengineering approaches for gene therapy of hemophilia A","volume":"9","author":"Brown","year":"2018","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B105","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.omtm.2018.03.004","article-title":"A rationally engineered capsid variant of AAV9 for systemic CNS-directed and peripheral tissue-detargeted gene delivery in neonates","volume":"9","author":"Wang","year":"2018","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/mt.2011.3","article-title":"A potential role of distinctively delayed blood clearance of recombinant adeno-associated virus serotype 9 in robust cardiac transduction","volume":"19","author":"Kotchey","year":"2011","journal-title":"Mol Ther."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.celrep.2015.07.019","article-title":"In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector","volume":"12","author":"Zinn","year":"2015","journal-title":"Cell Rep."},{"key":"B108","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.omtm.2018.07.006","article-title":"Efficient gene transfer to the central nervous system by single-stranded Anc80L65","volume":"10","author":"Hudry","year":"2018","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B109","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s12974-020-01963-6","article-title":"The overexpression of TDP-43 in astrocytes causes neurodegeneration via a PTP1B-mediated inflammatory response","volume":"17","author":"Lee","year":"2020","journal-title":"J Neuroinflamm."},{"key":"B110","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4103\/1673-5374.290881","article-title":"Microglia in neurodegenerative diseases","volume":"16","author":"Xu","year":"2021","journal-title":"Neural Regen Res."},{"key":"B111","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41593-021-00951-0","article-title":"Microglia contribute to the propagation of A\u03b2 into unaffected brain tissue","volume":"25","author":"d'Errico","year":"2022","journal-title":"Nat Neurosci."},{"key":"B112","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41593-021-00975-6","article-title":"TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration","volume":"25","author":"Xie","year":"2022","journal-title":"Nat Neurosci."},{"key":"B113","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/icb.2013.74","article-title":"Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy","volume":"92","author":"Pandya","year":"2014","journal-title":"Immunol Cell Biol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"134310","DOI":"10.1016\/j.neulet.2019.134310","article-title":"Targeting microglia with lentivirus and AAV: recent advances and remaining challenges","volume":"707","author":"Maes","year":"2019","journal-title":"Neurosci Lett."},{"key":"B115","doi-asserted-by":"publisher","first-page":"618020","DOI":"10.3389\/fnmol.2020.618020","article-title":"AAV targeting of glial cell types in the central and peripheral nervous system and relevance to human gene therapy","volume":"13","author":"O'Carroll","year":"2021","journal-title":"Front Mol Neurosci."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1038\/mt.2008.100","article-title":"Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles","volume":"16","author":"Li","year":"2008","journal-title":"Mol Ther."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/12491","article-title":"Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2","volume":"5","author":"Girod","year":"1999","journal-title":"Nat Med."},{"key":"B118","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1006\/viro.1999.0045","article-title":"Insertional mutagenesis of AAV2 capsid and the production of recombinant virus","volume":"265","author":"Rabinowitz","year":"1999","journal-title":"Virology."},{"key":"B119","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.molmed.2021.03.010","article-title":"Adeno-associated virus vector for central nervous system gene therapy","volume":"27","author":"Zhu","year":"2021","journal-title":"Trends Mol Med."},{"key":"B120","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/gt.2016.62","article-title":"Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism","volume":"23","author":"Powell","year":"2016","journal-title":"Gene Ther."},{"key":"B121","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nbt.3440","article-title":"Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain","volume":"34","author":"Deverman","year":"2016","journal-title":"Nat Biotechnol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/nn.4593","article-title":"Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems","volume":"20","author":"Chan","year":"2017","journal-title":"Nat Neurosci."},{"key":"B123","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ymthe.2018.01.018","article-title":"The neurotropic properties of AAV-PHP.B are limited to C57BL\/6J mice","volume":"26","author":"Hordeaux","year":"2018","journal-title":"Mol Ther."},{"key":"B124","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.ymthe.2019.07.017","article-title":"AAV-PHP.B administration results in a differential pattern of CNS biodistribution in non-human primates compared with mice","volume":"27","author":"Liguore","year":"2019","journal-title":"Mol Ther."},{"key":"B125","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.omtm.2019.10.007","article-title":"Selection of an efficient AAV vector for robust CNS transgene expression","volume":"15","author":"Hanlon","year":"2019","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B126","doi-asserted-by":"publisher","first-page":"e120474","DOI":"10.1172\/jci.insight.120474","article-title":"Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction","volume":"3","author":"Shao","year":"2018","journal-title":"JCI Insight."},{"key":"B127","doi-asserted-by":"publisher","first-page":"7752","DOI":"10.1128\/JVI.00675-12","article-title":"Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles","volume":"86","author":"Li","year":"2012","journal-title":"J Virol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.1128\/JVI.00254-08","article-title":"In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses","volume":"82","author":"Grimm","year":"2008","journal-title":"J Virol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1089\/hum.1998.9.4-477","article-title":"Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors","volume":"9","author":"Manning","year":"1998","journal-title":"Hum Gene Ther."},{"key":"B130","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1525-139X.2011.01026.x","article-title":"Complications of apheresis: complications of apheresis","volume":"25","author":"Kaplan","year":"2012","journal-title":"Semin Dialy."},{"key":"B131","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41598-020-57893-z","article-title":"Capsid-specific removal of circulating antibodies to adeno-associated virus vectors","volume":"10","author":"Bertin","year":"2020","journal-title":"Sci Rep."},{"key":"B132","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1128\/JVI.70.5.3227-3234.1996","article-title":"Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors","volume":"70","author":"Ferrari","year":"1996","journal-title":"J Virol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1128\/JVI.70.1.520-532.1996","article-title":"Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis","volume":"70","author":"Fisher","year":"1996","journal-title":"J Virol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/sj.mt.6300355","article-title":"Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose","volume":"16","author":"Wu","year":"2008","journal-title":"Mol Ther."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/mt.2011.72","article-title":"Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates","volume":"19","author":"Gray","year":"2011","journal-title":"Mol Ther."},{"key":"B136","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nrd.2018.110","article-title":"Gene therapy for neurological disorders: progress and prospects","volume":"17","author":"Deverman","year":"2018","journal-title":"Nat Rev Drug Discov."},{"key":"B137","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/mt.2009.255","article-title":"Effect of genome size on AAV vector packaging","volume":"18","author":"Wu","year":"2010","journal-title":"Mol Ther."},{"key":"B138","doi-asserted-by":"publisher","first-page":"673699","DOI":"10.3389\/fimmu.2021.673699","article-title":"Vectored immunotherapeutics for infectious diseases: can rAAVs be the game changers for fighting transmissible pathogens?","volume":"12","author":"Zhan","year":"2021","journal-title":"Front Immunol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3109\/07388551.2014.958978","article-title":"Phage antibody display libraries: a powerful antibody discovery platform for immunotherapy","volume":"36","author":"Zhao","year":"2016","journal-title":"Crit Rev Biotechnol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/s0165-5728(01)00242-9","article-title":"Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier","volume":"114","author":"Zhang","year":"2001","journal-title":"J Neuroimmunol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1046\/j.1471-4159.2001.00222.x","article-title":"Rapid transferrin efflux from brain to blood across the blood-brain barrier","volume":"76","author":"Zhang","year":"2001","journal-title":"J Neurochem."},{"key":"B142","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.brainres.2013.08.035","article-title":"Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn","volume":"1534","author":"Cooper","year":"2013","journal-title":"Brain Res."},{"key":"B143","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu Rev Biochem."},{"key":"B144","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/nbt772","article-title":"Immunomodulation of enzyme function in plants by single-domain antibody fragments","volume":"21","author":"Jobling","year":"2003","journal-title":"Nat Biotechnol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ymeth.2004.04.007","article-title":"Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering","volume":"34","author":"Ewert","year":"2004","journal-title":"Methods."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/980250","article-title":"scFv antibody: principles and clinical application","volume":"2012","author":"Ahmad","year":"2012","journal-title":"Clin Dev Immunol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"E1663","DOI":"10.3390\/biom10121663","article-title":"An inside job: applications of intracellular single domain antibodies","volume":"10","author":"Soetens","year":"2020","journal-title":"Biomolecules."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/S1359-6446(05)03554-3","article-title":"BiTEs: bispecific antibody constructs with unique anti-tumor activity","volume":"10","author":"Wolf","year":"2005","journal-title":"Drug Discov Today."},{"key":"B149","doi-asserted-by":"publisher","first-page":"E28","DOI":"10.3390\/antib8020028","article-title":"David vs. Goliath: the structure, function, and clinical prospects of antibody fragments","volume":"8","author":"Bates","year":"2019","journal-title":"Antibodies."},{"key":"B150","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jmb.2010.04.001","article-title":"Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion","volume":"399","author":"Johnson","year":"2010","journal-title":"J Mol Biol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1074\/jbc.R115.679811","article-title":"Nanobodies as probes for protein dynamics in vitro and in cells","volume":"291","author":"Dmitriev","year":"2016","journal-title":"J Biol Chem."},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809824","article-title":"AAV-mediated delivery of an anti-BACE1 VHH alleviates pathology in an Alzheimer's disease model","author":"Marino","year":"2022","journal-title":"EMBO Mol Med."},{"key":"B153","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3389\/fpls.2018.00130","article-title":"Nanobody-directed specific degradation of proteins by the 26S-proteasome in plants","volume":"9","author":"Baudisch","year":"2018","journal-title":"Front Plant Sci."},{"key":"B154","doi-asserted-by":"publisher","first-page":"15307","DOI":"10.1074\/jbc.REV120.012960","article-title":"Exploring cellular biochemistry with nanobodies","volume":"295","author":"Cheloha","year":"2020","journal-title":"J Biol Chem."},{"key":"B155","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1093\/hmg\/ddx207","article-title":"AAV9 delivered bispecific nanobody attenuates amyloid burden in the gelsolin amyloidosis mouse model","volume":"26","author":"Verhelle","year":"2017","journal-title":"Hum Mol Genet."},{"key":"B156","doi-asserted-by":"publisher","first-page":"632687","DOI":"10.3389\/fimmu.2021.632687","article-title":"Immunogenicity risk profile of nanobodies","volume":"12","author":"Ackaert","year":"2021","journal-title":"Front Immunol."},{"key":"B157","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1074\/jbc.M806889200","article-title":"General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold","volume":"284","author":"Vincke","year":"2009","journal-title":"J Biol Chem."},{"key":"B158","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","article-title":"The therapeutic potential of nanobodies","volume":"34","author":"Jov\u010devska","year":"2020","journal-title":"Biodrugs."},{"key":"B159","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nm0103-129","article-title":"Engineered antibodies","volume":"9","author":"Hudson","year":"2003","journal-title":"Nat Med."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.3390\/biom10121701","article-title":"Nanobodies right in the middle: intrabodies as toolbox to visualize and modulate antigens in the living cell","volume":"10","author":"Wagner","year":"2020","journal-title":"Biomolecules."},{"key":"B161","doi-asserted-by":"publisher","first-page":"286","DOI":"10.7150\/ijms.14152","article-title":"Enhancing transgene expression from recombinant AAV8 vectors in different tissues using woodchuck hepatitis virus post-transcriptional regulatory element","volume":"13","author":"Wang","year":"2016","journal-title":"Int J Med Sci."},{"key":"B162","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.omtn.2016.12.006","article-title":"Inclusion of the woodchuck hepatitis virus posttranscriptional regulatory element enhances AAV2-driven transduction of mouse and human retina","volume":"6","author":"Patr\u00edcio","year":"2017","journal-title":"Mol Ther Nucleic Acids."},{"key":"B163","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/mt.2014.114","article-title":"Liver-specific transcriptional modules identified by genome-wide in silico analysis enable efficient gene therapy in mice and non-human primates","volume":"22","author":"Chuah","year":"2014","journal-title":"Mol Ther."},{"key":"B164","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/mt.2014.178","article-title":"Genome-wide computational analysis reveals cardiomyocyte-specific transcriptional cis-regulatory motifs that enable efficient cardiac gene therapy","volume":"23","author":"Rincon","year":"2015","journal-title":"Mol Ther."},{"key":"B165","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41467-018-08283-7","article-title":"Next-generation muscle-directed gene therapy by in silico vector design","volume":"10","author":"Sarcar","year":"2019","journal-title":"Nat Commun."},{"key":"B166","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/jgm.2712","article-title":"Mir-142-3p target sequences reduce transgene-directed immunogenicity following intramuscular adeno-associated virus 1 vector-mediated gene delivery: reduction of transgene directed immune responses in AAV1 gene delivery","volume":"15","author":"Majowicz","year":"2013","journal-title":"J Gene Med."},{"key":"B167","doi-asserted-by":"publisher","first-page":"674242","DOI":"10.3389\/fimmu.2021.674242","article-title":"Novel combinatorial microRNA-binding sites in AAV vectors synergistically diminish antigen presentation and transgene immunity for efficient and stable transduction","volume":"12","author":"Muhuri","year":"2021","journal-title":"Front Immunol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0042-6822(03)00162-4","article-title":"Differential transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units","volume":"311","author":"K\u00fcgler","year":"2003","journal-title":"Virology."},{"key":"B169","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41434-019-0075-6","article-title":"Astrocyte-selective AAV gene therapy through the endogenous GFAP promoter results in robust transduction in the rat spinal cord following injury","volume":"26","author":"Griffin","year":"2019","journal-title":"Gene Ther."},{"key":"B170","doi-asserted-by":"publisher","first-page":"685802","DOI":"10.3389\/fneur.2021.685802","article-title":"Toward development of neuron specific transduction after systemic delivery of viral vectors","volume":"12","author":"Finneran","year":"2021","journal-title":"Front Neurol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fnmol.2016.00013","article-title":"Recombinant human myelin-associated glycoprotein promoter drives selective AAV-mediated transgene expression in oligodendrocytes","volume":"9","author":"von Jonquieres","year":"2016","journal-title":"Front Mol Neurosci."},{"key":"B172","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40478-018-0515-3","article-title":"White matter changes in Alzheimer's disease: a focus on myelin and oligodendrocytes","volume":"6","author":"Nasrabady","year":"2018","journal-title":"Acta Neuropathol Commun."},{"key":"B173","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nrneurol.2011.21","article-title":"White matter lesions in Parkinson disease","volume":"7","author":"Bohnen","year":"2011","journal-title":"Nat Rev Neurol."},{"key":"B174","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13041-021-00746-1","article-title":"GABAergic neuron-specific whole-brain transduction by AAV-PHP.B incorporated with a new GAD65 promoter","volume":"14","author":"Hoshino","year":"2021","journal-title":"Mol Brain."},{"key":"B175","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/2051-5960-1-34","article-title":"Tau pathology induces loss of GABAergic interneurons leading to altered synaptic plasticity and behavioral impairments","volume":"1","author":"Levenga","year":"2013","journal-title":"Acta Neuropathol Commun."},{"key":"B176","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/brain\/awaa376","article-title":"Alzheimer's disease brain-derived extracellular vesicles spread tau pathology in interneurons","volume":"144","author":"Ruan","year":"2021","journal-title":"Brain."},{"key":"B177","doi-asserted-by":"publisher","first-page":"37","DOI":"10.5493\/wjem.v6.i2.37","article-title":"MicroRNA-regulated viral vectors for gene therapy","volume":"6","author":"Geisler","year":"2016","journal-title":"World J Exp Med."},{"key":"B178","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/mt.2010.279","article-title":"MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression","volume":"19","author":"Xie","year":"2011","journal-title":"Mol Ther."},{"key":"B179","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1023\/a:1007677003387","article-title":"Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000)","volume":"25","author":"Eng","year":"2000","journal-title":"Neurochem Res."},{"key":"B180","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/j.0953-816x.2003.03147.x","article-title":"Lesion-dependent regulation of transgene expression in the rat brain using a human glial fibrillary acidic protein-lentiviral vector","volume":"19","author":"Jakobsson","year":"2004","journal-title":"Eur J Neurosci."},{"key":"B181","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1038\/s41467-019-14198-8","article-title":"Identification of region-specific astrocyte subtypes at single cell resolution","volume":"11","author":"Batiuk","year":"2020","journal-title":"Nat Commun."},{"key":"B182","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3390\/brainsci10030168","article-title":"No longer underappreciated: the emerging concept of astrocyte heterogeneity in neuroscience","volume":"10","author":"Pestana","year":"2020","journal-title":"Brain Sci."},{"key":"B183","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1750-1326-7-39","article-title":"Transient pharmacologic lowering of A\u03b2 production prior to deposition results in sustained reduction of amyloid plaque pathology","volume":"7","author":"Das","year":"2012","journal-title":"Mol Neurodegener."},{"key":"B184","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.1523\/JNEUROSCI.4560-08.2009","article-title":"Suppression of amyloid deposition leads to long-term reductions in Alzheimer's pathologies in Tg2576 mice","volume":"29","author":"Karlnoski","year":"2009","journal-title":"J Neurosci."},{"key":"B185","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1089\/hum.2018.234","article-title":"Five years of successful inducible transgene expression following locoregional adeno-associated virus delivery in nonhuman primates with no detectable immunity","volume":"30","author":"Guilbaud","year":"2019","journal-title":"Hum Gene Ther."},{"key":"B186","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1089\/10430340260201707","article-title":"Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression","volume":"13","author":"Latta-Mahieu","year":"2002","journal-title":"Hum Gene Ther."},{"key":"B187","doi-asserted-by":"publisher","first-page":"11605","DOI":"10.1128\/JVI.76.22.11605-11611.2002","article-title":"Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus","volume":"76","author":"Favre","year":"2002","journal-title":"J Virol."},{"key":"B188","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/gt.2014.22","article-title":"Developing a potentially immunologically inert tetracycline-regulatable viral vector for gene therapy in the peripheral nerve","volume":"21","author":"Hoyng","year":"2014","journal-title":"Gene Ther."},{"key":"B189","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1093\/brain\/awy158","article-title":"Immune-evasive gene switch enables regulated delivery of chondroitinase after spinal cord injury","volume":"141","author":"Burnside","year":"2018","journal-title":"Brain."},{"key":"B190","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0304-3940(03)01077-2","article-title":"Minocycline-induced activation of tetracycline-responsive promoter","volume":"352","author":"Chtarto","year":"2003","journal-title":"Neurosci Lett."},{"key":"B191","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1365-2133.1996.tb06972.x","article-title":"Safety of long-term high-dose minocycline in the treatment of acne","volume":"134","author":"Goulden","year":"1996","journal-title":"Br J Dermatol."},{"key":"B192","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1177\/00912700122010753","article-title":"The risk of liver damage associated with minocycline: a comparative study","volume":"41","author":"Seaman","year":"2001","journal-title":"J Clin Pharmacol."},{"key":"B193","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/417074a","article-title":"Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice","volume":"417","author":"Zhu","year":"2002","journal-title":"Nature."},{"key":"B194","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/77528","article-title":"Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease","volume":"6","author":"Chen","year":"2000","journal-title":"Nat Med."},{"key":"B195","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1523\/JNEUROSCI.22-05-01763.2002","article-title":"Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease","volume":"22","author":"Wu","year":"2002","journal-title":"J Neurosci."},{"key":"B196","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/00002826-200301000-00005","article-title":"Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease","volume":"26","author":"Thomas","year":"2003","journal-title":"Clin Neuropharmacol."},{"key":"B197","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/ana.10242","article-title":"Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury","volume":"52","author":"Arvin","year":"2002","journal-title":"Ann Neurol."},{"key":"B198","doi-asserted-by":"publisher","first-page":"1860476","DOI":"10.1080\/19420862.2020.1860476","article-title":"Antibodies to watch in 2021","volume":"13","author":"Kaplon","year":"2021","journal-title":"mAbs."},{"key":"B199","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2217\/imt.14.7","article-title":"Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis","volume":"6","author":"Hersh","year":"2014","journal-title":"Immunotherapy."},{"key":"B200","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med."},{"key":"B201","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine","volume":"377","author":"Goadsby","year":"2017","journal-title":"N Engl J Med."},{"key":"B202","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine","volume":"377","author":"Silberstein","year":"2017","journal-title":"N Engl J Med."},{"key":"B203","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","article-title":"Eculizumab: a review in generalized myasthenia gravis","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs."},{"key":"B204","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s40265-020-01297-w","article-title":"Eculizumab: a review in neuromyelitis optica spectrum disorder","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs."},{"key":"B205","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat Rev Genet."},{"key":"B206","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/d41573-021-00017-7","article-title":"The clinical landscape for AAV gene therapies","volume":"20","author":"Kuzmin","year":"2021","journal-title":"Nat Rev Drug Discov."},{"key":"B207","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1146\/annurev-animal-021419-083831","article-title":"Applications of nanobodies","volume":"9","author":"Muyldermans","year":"2021","journal-title":"Annu Rev Anim Biosci."},{"key":"B208","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1177\/1535370217694100","article-title":"Blood-brain barrier-on-a-chip: Microphysiological systems that capture the complexity of the blood-central nervous system interface","volume":"242","author":"Phan","year":"2017","journal-title":"Exp Biol Med."},{"key":"B209","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature25032","article-title":"The rise of three-dimensional human brain cultures","volume":"553","author":"Pa\u015fca","year":"2018","journal-title":"Nature."},{"key":"B210","doi-asserted-by":"publisher","first-page":"623950","DOI":"10.3389\/fmedt.2020.623950","article-title":"In vitro models of the blood-brain barrier: tools in translational medicine","volume":"2","author":"Williams-Medina","year":"2020","journal-title":"Front Med Technol."},{"key":"B211","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fnins.2014.00235","article-title":"New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease","volume":"8","author":"Fuller","year":"2014","journal-title":"Front Neurosci."},{"key":"B212","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-1-61779-968-6_2","article-title":"Introduction to heavy chain antibodies and derived Nanobodies","volume":"911","author":"Vincke","year":"2012","journal-title":"Methods Mol Biol."},{"key":"B213","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jalz.2013.05.1762","article-title":"Revisiting the framework of the National Institute on Aging-Alzheimer's Association diagnostic criteria","volume":"9","author":"Carrillo","year":"2013","journal-title":"Alzheimers Dement."},{"key":"B214","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol."},{"key":"B215","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/brain\/awv404","article-title":"Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease","volume":"139","author":"Rodriguez-Vieitez","year":"2016","journal-title":"Brain."},{"key":"B216","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","article-title":"The cellular phase of Alzheimer's disease","volume":"164","author":"De Strooper","year":"2016","journal-title":"Cell."},{"key":"B217","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1089\/hum.2017.042","article-title":"Manufacturing clinical grade recombinant adeno-associated virus using invertebrate cell lines","volume":"28","author":"Kotin","year":"2017","journal-title":"Hum Gene Ther."},{"key":"B218","doi-asserted-by":"publisher","first-page":"16031","DOI":"10.1038\/mtm.2016.31","article-title":"A scalable method for the production of high-titer and high-quality adeno-associated type 9 vectors using the HSV platform","volume":"3","author":"Adamson-Small","year":"2016","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B219","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1006\/mthe.2000.0132","article-title":"Selective Rep-Cap gene amplification as a mechanism for high-titer recombinant AAV production from stable cell lines","volume":"2","author":"Liu","year":"2000","journal-title":"Mol Ther."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.870799\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T08:21:35Z","timestamp":1649751695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.870799\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":219,"alternative-id":["10.3389\/fneur.2022.870799"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.870799","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,12]]},"article-number":"870799"}}